Skip to main content

SeraCare Licenses Genetic Testing Controls for CF

NEW YORK (GenomeWeb News) – SeraCare Life Sciences today said that it has licensed from Sacred Heart Medical Center & Children’s Hospital in Spokane, Wash., exclusive rights to controls for genetic testing including screening for cystic fibrosis and for diseases common among Ashkenazi Jews.
 
The Milford, Mass.-based firm announced the licensing deal concurrent with the launch of its new genetic testing controls business line. This business line initially includes controls for warfarin sensitivity testing and thrombophilia testing, which were developed internally by SeraCare.
 
“In the coming months, we will continue to make key additions to the genetic controls product portfolio as this business line plays an important role in the company’s near-term growth strategy and future profitability,” SeraCare President and CEO Susan Vogt said in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.